27 March 2024 - NICE has published final evidence-based recommendations on the use of daratumumab (Darzalex) for the treatment of adults with newly diagnosed systemic amyloid light-chain amyloidosis.

Daratumumab, when used in combination with bortezomib, cyclophosphamide and dexamethasone, is recommended as an option for the treatment of adults with newly diagnosed systemic amyloid light-chain amyloidosis only if daratumumab is stopped after 24 cycles of treatment, or earlier if the condition progresses, and Janssen provides daratumumab according to the commercial arrangement.

Read NICE technology appraisal guidance